Open 7 , e2421305 (2024)
I might suggest this approach to a patient who is having difficulty with side effects, or someone who is having brisk weight loss on low doses
The right path will depend on your health needs, financial situation, and personal preferences
On May 15th, the journal Nature published a research paper titled "GLP-1-directed NMDA receptor antagonism for obesity treatment" by the Novo Nordisk team and the team led by Christoffer Clemmensen at the University of Copenhagen
This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made
Theres no tapering-off regimen either, but thats true about many other medications, he notes